OBJECTIVE	The authors present the Hungarian interim analysis and experience with the BCIRG 001 randomized , multicentric , phase III clinical trial comparing TAC ( docetaxel , doxorubicin , cyclophosphamide ) and FAC ( 5-fluorouracil , doxorubicin , cyclophosphamide ) in the adjuvant treatment of node positive breast cancer patients .\